Brief: Rigel's Fostamatinib Enters Phase 3 Clinical Trial In Japan With Kissei Pharmaceuticals For The Treatment Of Chronic Immune Thrombocytopenia

Kissei Pharmaceutical

23/09/2019 12:38

Sept 23 (Reuters) - Rigel Pharmaceuticals Inc  RIGL.O :
    * RIGEL'S FOSTAMATINIB ENTERS PHASE 3 CLINICAL TRIAL IN
JAPAN WITH
KISSEI PHARMACEUTICALS FOR THE TREATMENT OF CHRONIC IMMUNE
THROMBOCYTOPENIA
    * RIGEL PHARMACEUTICALS INC - TRIAL RESULTS TO BE USED TO
SUPPORT
NEW DRUG APPLICATION THAT KISSEI PLANS TO FILE IN JAPAN IN LATE
2021 OR EARLY 2022

Source text for Eikon:  ID:nPn7PDvxQa 
Further company coverage:  RIGL.O 

 ((Reuters.Briefs@thomsonreuters.com;))